How Certara MIDD Experts Overcame Client Regulatory Challenges
Certara’s Model-Informed Drug Development (MIDD) approach leverages an integrated, quantitative systems methodology to accelerate regulatory…
CertaraApril 8, 2025
Standardizing Real World Data in Rare Disease: ATHN’s Journey
Learn how Certara helped ATHN standardize Real World Data for regulatory submissions, advancing rare disease…
CertaraApril 8, 2025
Mechanistic Modeling to Meet Challenges in ADC Development
April 4, 2025 Navigating the challenges in antibody-drug conjugates (ADCs) development requires overcoming complex hurdles…
CertaraApril 4, 2025
Unlocking the Power of Oligonucleotide Therapeutics: A Model-Informed Approach with Certara & Ionis
Clinical Pharmacology Leader, Ionis Pharmaceuticals Pratap Singh, Ph.D., is currently an Executive Director and Franchise…
CertaraApril 3, 2025
Model-Based Meta-Analysis for All Phases of Drug Development: Capturing the Full Potential of Published Clinical Trial Outcomes [APAC Webinar]
Vice President, Quantitative Science Services, Certara Matt advances the integration of published clinical outcomes data…
CertaraApril 3, 2025
Unlocking Success with Phoenix Hosted: Real-World Customer Stories
As part of our Phoenix Hosted webinar, we highlighted three customer success stories showcasing the…
CertaraApril 2, 2025
Calculating AUC (Linear and Log-linear)
AUC calculations are simple but nuanced. In this blog, we look at how to calculate…
CertaraApril 2, 2025
Accumulation: What It Means and How to Calculate It
Watch our on demand webinar to discover fast, flexible, frictionless PK/PD workflows with Phoenix Cloud.…
CertaraApril 2, 2025
